All trades / RVMD
RVMD
Revolution Medicines, Inc.
492Open-market trades
—Avg 90d after buys
—Avg 90d after sales
—Avg 180d after buys
Price and insider prints
No daily prices for this ticker.
Trades
| Date | Form 4 | Ticker | Insider | Title | Side | Shares | Value | 90d | 180d |
|---|---|---|---|---|---|---|---|---|---|
| 9/16/2026 | Form 4 | RVMD 10b5-1 | Cislini JeffJeff Cislini has served as our Senior Vice President, General Counsel and Secretary since September 2022 and as our Vice President, Deputy General Counsel from June 2020 to September 2022. Prior to joining Revolution Medicines, Mr. Cislini held positions of increasing responsibility at Atara Biotherapeutics, Inc., a biotechnology company, from September 2018 to June 2020, most recently as its Vice President, Legal, Corporate and Contracts and Corporate Secretary. Mr. Cislini was an attorney at the law firms of O’Melveny & Myers LLP from 2007 to 2018 and Wilson Sonsini Goodrich and Rosati, P.C. from 2001 to 2007. He received a B.A.S. with dual majors in Economics and Land Resources Planning from Stanford… | SVP & General Counsel | SELL | 3,314 | $660.5K | — | — |
| 9/16/2026 | Form 4 | RVMD 10b5-1 | Cislini JeffJeff Cislini has served as our Senior Vice President, General Counsel and Secretary since September 2022 and as our Vice President, Deputy General Counsel from June 2020 to September 2022. Prior to joining Revolution Medicines, Mr. Cislini held positions of increasing responsibility at Atara Biotherapeutics, Inc., a biotechnology company, from September 2018 to June 2020, most recently as its Vice President, Legal, Corporate and Contracts and Corporate Secretary. Mr. Cislini was an attorney at the law firms of O’Melveny & Myers LLP from 2007 to 2018 and Wilson Sonsini Goodrich and Rosati, P.C. from 2001 to 2007. He received a B.A.S. with dual majors in Economics and Land Resources Planning from Stanford… | SVP & General Counsel | SELL | 52 | $10.1K | — | — |
| 9/16/2026 | Form 4 | RVMD 10b5-1 | Sandler Alan B. | Chief Development Officer | SELL | 336 | $67.0K | — | — |
| 9/16/2026 | Form 4 | RVMD 10b5-1 | Sandler Alan B. | Chief Development Officer | SELL | 5 | $974.79 | — | — |
| 9/16/2026 | Form 4 | RVMD 10b5-1 | Kelsey Stephen Michael | Officer | SELL | 5,484 | $1.09M | −0.93%hist | +26.2%hist |
| 9/16/2026 | Form 4 | RVMD 10b5-1 | Kelsey Stephen Michael | Officer | SELL | 85 | $16.6K | −0.93%hist | +26.2%hist |
| 9/16/2026 | Form 4 | RVMD 10b5-1 | Mancini AnthonyAnthony Mancini has served as our Chief Global Commercialization Officer since March 2025. Previously, Mr. Mancini served as Executive Vice President & Chief Operating Officer at Genmab A/S from March 2020 until March 2025, where he played a pivotal role in transforming the company from an R&D focused organization to an end-to-end enterprise. Prior to Genmab, Mr. Mancini spent nearly 24 years at Bristol-Myers Squibb, where he held progressively senior leadership roles across multiple geographies, including in the U.S., Europe, Canada, Australia and New Zealand. He received a B.S. in Biochemistry from the University of Ottawa and an M.B.A. in International Management, from Clemson University. Jeffrey Cislini… | Officer | SELL | 27 | $5.3K | — | — |
| 9/16/2026 | Form 4 | RVMD 10b5-1 | Mancini AnthonyAnthony Mancini has served as our Chief Global Commercialization Officer since March 2025. Previously, Mr. Mancini served as Executive Vice President & Chief Operating Officer at Genmab A/S from March 2020 until March 2025, where he played a pivotal role in transforming the company from an R&D focused organization to an end-to-end enterprise. Prior to Genmab, Mr. Mancini spent nearly 24 years at Bristol-Myers Squibb, where he held progressively senior leadership roles across multiple geographies, including in the U.S., Europe, Canada, Australia and New Zealand. He received a B.S. in Biochemistry from the University of Ottawa and an M.B.A. in International Management, from Clemson University. Jeffrey Cislini… | Officer | SELL | 1,747 | $348.2K | — | — |
| 9/16/2026 | Form 4 | RVMD 10b5-1 | Horn Margaret AMs. Horn has served on the board of directors of Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a biotechnology company, since December 2022. She received a B.S. in Pharmacy from the University of the Sciences in Philadelphia, a J.D. from the Villanova University Charles Widger School of Law and an executive M.B.A. from the Pennsylvania State University. Alan Sandler, M.D. has served as our Chief Development Officer since September 2025. Previously, Dr. Sandler served as Chief Medical Officer of ALX Oncology Holdings, Inc. from November 2024 until September 2025, where he led clinical strategy and advanced the company’s immune-oncology pipeline. Before ALX Oncology Holdings, he was Chief Medical Officer of… | Chief Operating Officer | SELL | 76 | $14.8K | — | — |
| 9/16/2026 | Form 4 | RVMD 10b5-1 | Horn Margaret AMs. Horn has served on the board of directors of Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a biotechnology company, since December 2022. She received a B.S. in Pharmacy from the University of the Sciences in Philadelphia, a J.D. from the Villanova University Charles Widger School of Law and an executive M.B.A. from the Pennsylvania State University. Alan Sandler, M.D. has served as our Chief Development Officer since September 2025. Previously, Dr. Sandler served as Chief Medical Officer of ALX Oncology Holdings, Inc. from November 2024 until September 2025, where he led clinical strategy and advanced the company’s immune-oncology pipeline. Before ALX Oncology Holdings, he was Chief Medical Officer of… | Chief Operating Officer | SELL | 4,891 | $974.8K | — | — |
| 9/16/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 213 | $41.5K | — | — |
| 9/16/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 13,775 | $2.75M | — | — |
| 9/16/2026 | Form 4 | RVMD 10b5-1 | Anders JackJack Anders has served as our Chief Financial Officer since September 2022, as our Senior Vice President, Finance from March 2021 to September 2022 and as our Vice President, Finance from August 2018 to March 2021. Prior to joining Revolution Medicines, Mr. Anders held various positions of increasing responsibility at Depomed, Inc., a specialty pharmaceutical company, from 2006 to July 2018, most recently as its Vice President of Finance. Mr. Anders held various managerial roles in finance and accounting at Elan Pharmaceuticals, Yahoo! and Novellus Systems. Mr. Anders began his career in the life sciences practice at PricewaterhouseCoopers LLP. He received a B.A. in Economics, with an emphasis in… | Chief Financial Officer | SELL | 61 | $11.9K | — | — |
| 9/16/2026 | Form 4 | RVMD 10b5-1 | Anders JackJack Anders has served as our Chief Financial Officer since September 2022, as our Senior Vice President, Finance from March 2021 to September 2022 and as our Vice President, Finance from August 2018 to March 2021. Prior to joining Revolution Medicines, Mr. Anders held various positions of increasing responsibility at Depomed, Inc., a specialty pharmaceutical company, from 2006 to July 2018, most recently as its Vice President of Finance. Mr. Anders held various managerial roles in finance and accounting at Elan Pharmaceuticals, Yahoo! and Novellus Systems. Mr. Anders began his career in the life sciences practice at PricewaterhouseCoopers LLP. He received a B.A. in Economics, with an emphasis in… | Chief Financial Officer | SELL | 3,992 | $795.6K | — | — |
| 9/11/2026 | Form 4 | RVMD 10b5-1 | Kelsey Stephen Michael | Officer | SELL | 3,270 | $673.0K | −0.93%hist | +26.2%hist |
| 9/11/2026 | Form 4 | RVMD 10b5-1 | Kelsey Stephen Michael | Officer | SELL | 4,995 | $1.02M | −0.93%hist | +26.2%hist |
| 9/11/2026 | Form 4 | RVMD 10b5-1 | Kelsey Stephen Michael | Officer | SELL | 17,949 | $3.66M | −0.93%hist | +26.2%hist |
| 9/11/2026 | Form 4 | RVMD 10b5-1 | Kelsey Stephen Michael | Officer | SELL | 18,869 | $3.83M | −0.93%hist | +26.2%hist |
| 9/11/2026 | Form 4 | RVMD 10b5-1 | Kelsey Stephen Michael | Officer | SELL | 21,447 | $4.33M | −0.93%hist | +26.2%hist |
| 9/11/2026 | Form 4 | RVMD 10b5-1 | Kelsey Stephen Michael | Officer | SELL | 13,368 | $2.68M | −0.93%hist | +26.2%hist |
| 9/11/2026 | Form 4 | RVMD 10b5-1 | Kelsey Stephen Michael | Officer | SELL | 11,833 | $2.37M | −0.93%hist | +26.2%hist |
| 9/11/2026 | Form 4 | RVMD 10b5-1 | Kelsey Stephen Michael | Officer | SELL | 800 | $158.8K | −0.93%hist | +26.2%hist |
| 9/10/2026 | Form 4 | RVMD 10b5-1 | Mancini AnthonyAnthony Mancini has served as our Chief Global Commercialization Officer since March 2025. Previously, Mr. Mancini served as Executive Vice President & Chief Operating Officer at Genmab A/S from March 2020 until March 2025, where he played a pivotal role in transforming the company from an R&D focused organization to an end-to-end enterprise. Prior to Genmab, Mr. Mancini spent nearly 24 years at Bristol-Myers Squibb, where he held progressively senior leadership roles across multiple geographies, including in the U.S., Europe, Canada, Australia and New Zealand. He received a B.S. in Biochemistry from the University of Ottawa and an M.B.A. in International Management, from Clemson University. Jeffrey Cislini… | Officer | SELL | 6,019 | $1.22M | — | — |
| 9/10/2026 | Form 4 | RVMD 10b5-1 | Mancini AnthonyAnthony Mancini has served as our Chief Global Commercialization Officer since March 2025. Previously, Mr. Mancini served as Executive Vice President & Chief Operating Officer at Genmab A/S from March 2020 until March 2025, where he played a pivotal role in transforming the company from an R&D focused organization to an end-to-end enterprise. Prior to Genmab, Mr. Mancini spent nearly 24 years at Bristol-Myers Squibb, where he held progressively senior leadership roles across multiple geographies, including in the U.S., Europe, Canada, Australia and New Zealand. He received a B.S. in Biochemistry from the University of Ottawa and an M.B.A. in International Management, from Clemson University. Jeffrey Cislini… | Officer | SELL | 5,530 | $1.13M | — | — |
| 9/10/2026 | Form 4 | RVMD 10b5-1 | Mancini AnthonyAnthony Mancini has served as our Chief Global Commercialization Officer since March 2025. Previously, Mr. Mancini served as Executive Vice President & Chief Operating Officer at Genmab A/S from March 2020 until March 2025, where he played a pivotal role in transforming the company from an R&D focused organization to an end-to-end enterprise. Prior to Genmab, Mr. Mancini spent nearly 24 years at Bristol-Myers Squibb, where he held progressively senior leadership roles across multiple geographies, including in the U.S., Europe, Canada, Australia and New Zealand. He received a B.S. in Biochemistry from the University of Ottawa and an M.B.A. in International Management, from Clemson University. Jeffrey Cislini… | Officer | SELL | 2,420 | $496.2K | — | — |
| 9/10/2026 | Form 4 | RVMD 10b5-1 | Mancini AnthonyAnthony Mancini has served as our Chief Global Commercialization Officer since March 2025. Previously, Mr. Mancini served as Executive Vice President & Chief Operating Officer at Genmab A/S from March 2020 until March 2025, where he played a pivotal role in transforming the company from an R&D focused organization to an end-to-end enterprise. Prior to Genmab, Mr. Mancini spent nearly 24 years at Bristol-Myers Squibb, where he held progressively senior leadership roles across multiple geographies, including in the U.S., Europe, Canada, Australia and New Zealand. He received a B.S. in Biochemistry from the University of Ottawa and an M.B.A. in International Management, from Clemson University. Jeffrey Cislini… | Officer | SELL | 1,179 | $243.0K | — | — |
| 9/10/2026 | Form 4 | RVMD 10b5-1 | Mancini AnthonyAnthony Mancini has served as our Chief Global Commercialization Officer since March 2025. Previously, Mr. Mancini served as Executive Vice President & Chief Operating Officer at Genmab A/S from March 2020 until March 2025, where he played a pivotal role in transforming the company from an R&D focused organization to an end-to-end enterprise. Prior to Genmab, Mr. Mancini spent nearly 24 years at Bristol-Myers Squibb, where he held progressively senior leadership roles across multiple geographies, including in the U.S., Europe, Canada, Australia and New Zealand. He received a B.S. in Biochemistry from the University of Ottawa and an M.B.A. in International Management, from Clemson University. Jeffrey Cislini… | Officer | SELL | 300 | $62.2K | — | — |
| 9/8/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 706 | $145.9K | −52.8%hist | −68.8%hist |
| 9/8/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 999 | $207.1K | −52.8%hist | −68.8%hist |
| 9/8/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 3,587 | $748.1K | −52.8%hist | −68.8%hist |
| 9/8/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 2,853 | $597.9K | −52.8%hist | −68.8%hist |
| 9/8/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 4,730 | $995.7K | −52.8%hist | −68.8%hist |
| 9/8/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 3,844 | $812.5K | −52.8%hist | −68.8%hist |
| 9/8/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 371 | $78.8K | −52.8%hist | −68.8%hist |
| 8/31/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 300 | $60.2K | −52.8%hist | −68.8%hist |
| 8/31/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 6,597 | $1.33M | −52.8%hist | −68.8%hist |
| 8/31/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 12,919 | $2.62M | −52.8%hist | −68.8%hist |
| 8/31/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 26,160 | $5.32M | −52.8%hist | −68.8%hist |
| 8/31/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 7,271 | $1.49M | −52.8%hist | −68.8%hist |
| 8/31/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 2,128 | $436.6K | −52.8%hist | −68.8%hist |
| 8/31/2026 | Form 4 | RVMD 10b5-1 | Kim Lorence H. | Director | SELL | 625 | $128.8K | −52.8%hist | −68.8%hist |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | Cislini JeffJeff Cislini has served as our Senior Vice President, General Counsel and Secretary since September 2022 and as our Vice President, Deputy General Counsel from June 2020 to September 2022. Prior to joining Revolution Medicines, Mr. Cislini held positions of increasing responsibility at Atara Biotherapeutics, Inc., a biotechnology company, from September 2018 to June 2020, most recently as its Vice President, Legal, Corporate and Contracts and Corporate Secretary. Mr. Cislini was an attorney at the law firms of O’Melveny & Myers LLP from 2007 to 2018 and Wilson Sonsini Goodrich and Rosati, P.C. from 2001 to 2007. He received a B.A.S. with dual majors in Economics and Land Resources Planning from Stanford… | General Counsel | SELL | 3,400 | $704.6K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | Cislini JeffJeff Cislini has served as our Senior Vice President, General Counsel and Secretary since September 2022 and as our Vice President, Deputy General Counsel from June 2020 to September 2022. Prior to joining Revolution Medicines, Mr. Cislini held positions of increasing responsibility at Atara Biotherapeutics, Inc., a biotechnology company, from September 2018 to June 2020, most recently as its Vice President, Legal, Corporate and Contracts and Corporate Secretary. Mr. Cislini was an attorney at the law firms of O’Melveny & Myers LLP from 2007 to 2018 and Wilson Sonsini Goodrich and Rosati, P.C. from 2001 to 2007. He received a B.A.S. with dual majors in Economics and Land Resources Planning from Stanford… | General Counsel | SELL | 17,323 | $3.61M | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | Cislini JeffJeff Cislini has served as our Senior Vice President, General Counsel and Secretary since September 2022 and as our Vice President, Deputy General Counsel from June 2020 to September 2022. Prior to joining Revolution Medicines, Mr. Cislini held positions of increasing responsibility at Atara Biotherapeutics, Inc., a biotechnology company, from September 2018 to June 2020, most recently as its Vice President, Legal, Corporate and Contracts and Corporate Secretary. Mr. Cislini was an attorney at the law firms of O’Melveny & Myers LLP from 2007 to 2018 and Wilson Sonsini Goodrich and Rosati, P.C. from 2001 to 2007. He received a B.A.S. with dual majors in Economics and Land Resources Planning from Stanford… | General Counsel | SELL | 25,817 | $5.40M | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | Cislini JeffJeff Cislini has served as our Senior Vice President, General Counsel and Secretary since September 2022 and as our Vice President, Deputy General Counsel from June 2020 to September 2022. Prior to joining Revolution Medicines, Mr. Cislini held positions of increasing responsibility at Atara Biotherapeutics, Inc., a biotechnology company, from September 2018 to June 2020, most recently as its Vice President, Legal, Corporate and Contracts and Corporate Secretary. Mr. Cislini was an attorney at the law firms of O’Melveny & Myers LLP from 2007 to 2018 and Wilson Sonsini Goodrich and Rosati, P.C. from 2001 to 2007. He received a B.A.S. with dual majors in Economics and Land Resources Planning from Stanford… | General Counsel | SELL | 2,540 | $534.1K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | Cislini JeffJeff Cislini has served as our Senior Vice President, General Counsel and Secretary since September 2022 and as our Vice President, Deputy General Counsel from June 2020 to September 2022. Prior to joining Revolution Medicines, Mr. Cislini held positions of increasing responsibility at Atara Biotherapeutics, Inc., a biotechnology company, from September 2018 to June 2020, most recently as its Vice President, Legal, Corporate and Contracts and Corporate Secretary. Mr. Cislini was an attorney at the law firms of O’Melveny & Myers LLP from 2007 to 2018 and Wilson Sonsini Goodrich and Rosati, P.C. from 2001 to 2007. He received a B.A.S. with dual majors in Economics and Land Resources Planning from Stanford… | General Counsel | SELL | 4,500 | $951.0K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | Cislini JeffJeff Cislini has served as our Senior Vice President, General Counsel and Secretary since September 2022 and as our Vice President, Deputy General Counsel from June 2020 to September 2022. Prior to joining Revolution Medicines, Mr. Cislini held positions of increasing responsibility at Atara Biotherapeutics, Inc., a biotechnology company, from September 2018 to June 2020, most recently as its Vice President, Legal, Corporate and Contracts and Corporate Secretary. Mr. Cislini was an attorney at the law firms of O’Melveny & Myers LLP from 2007 to 2018 and Wilson Sonsini Goodrich and Rosati, P.C. from 2001 to 2007. He received a B.A.S. with dual majors in Economics and Land Resources Planning from Stanford… | General Counsel | SELL | 3,314 | $702.8K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 5,128 | $1.06M | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 24,917 | $5.19M | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 35,938 | $7.52M | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 3,813 | $801.7K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 6,583 | $1.39M | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 3,621 | $767.9K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 190 | $39.4K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 951 | $198.2K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 1,351 | $282.7K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 136 | $28.6K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 245 | $51.8K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 127 | $26.9K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 177 | $36.7K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 937 | $195.2K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 1,405 | $294.0K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 126 | $26.5K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 229 | $48.4K | — | — |
| 8/21/2026 | Form 4 | RVMD 10b5-1 | GOLDSMITH MARK A | Director and Officer | SELL | 126 | $26.7K | — | — |
| 6/29/2026 | Form 4 | RVMD 10b5-1 | Patel SushilSushil Patel has served as a member of our Board and as our Chief Executive Officer since April 2024. Previously, Dr. Patel served as our Chief Strategy Officer from January 2023 to April 2024 and as our Chief Commercial Officer from May 2021 to January 2023. Prior to joining Replimune, Dr. Patel served as VP, Franchise Head for Lung, Skin, Tumor Agnostic, and Rare Cancers at Genentech, Inc. since April 2018, and previously held various positions of increasing responsibility at Genentech, Inc. since 2002, including global launch lead and lifecycle leader for Tecentriq in lung cancer. From 1999 to 2002, Dr. Patel served as Senior Consultant at Front Line Strategic Management Consulting. From 1996 to 1999,… | Director | SELL | 300 | $55.0K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 4 | RVMD 10b5-1 | Patel SushilSushil Patel has served as a member of our Board and as our Chief Executive Officer since April 2024. Previously, Dr. Patel served as our Chief Strategy Officer from January 2023 to April 2024 and as our Chief Commercial Officer from May 2021 to January 2023. Prior to joining Replimune, Dr. Patel served as VP, Franchise Head for Lung, Skin, Tumor Agnostic, and Rare Cancers at Genentech, Inc. since April 2018, and previously held various positions of increasing responsibility at Genentech, Inc. since 2002, including global launch lead and lifecycle leader for Tecentriq in lung cancer. From 1999 to 2002, Dr. Patel served as Senior Consultant at Front Line Strategic Management Consulting. From 1996 to 1999,… | Director | SELL | 900 | $166.1K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 4 | RVMD 10b5-1 | Patel SushilSushil Patel has served as a member of our Board and as our Chief Executive Officer since April 2024. Previously, Dr. Patel served as our Chief Strategy Officer from January 2023 to April 2024 and as our Chief Commercial Officer from May 2021 to January 2023. Prior to joining Replimune, Dr. Patel served as VP, Franchise Head for Lung, Skin, Tumor Agnostic, and Rare Cancers at Genentech, Inc. since April 2018, and previously held various positions of increasing responsibility at Genentech, Inc. since 2002, including global launch lead and lifecycle leader for Tecentriq in lung cancer. From 1999 to 2002, Dr. Patel served as Senior Consultant at Front Line Strategic Management Consulting. From 1996 to 1999,… | Director | SELL | 1,100 | $204.5K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 4 | RVMD 10b5-1 | Patel SushilSushil Patel has served as a member of our Board and as our Chief Executive Officer since April 2024. Previously, Dr. Patel served as our Chief Strategy Officer from January 2023 to April 2024 and as our Chief Commercial Officer from May 2021 to January 2023. Prior to joining Replimune, Dr. Patel served as VP, Franchise Head for Lung, Skin, Tumor Agnostic, and Rare Cancers at Genentech, Inc. since April 2018, and previously held various positions of increasing responsibility at Genentech, Inc. since 2002, including global launch lead and lifecycle leader for Tecentriq in lung cancer. From 1999 to 2002, Dr. Patel served as Senior Consultant at Front Line Strategic Management Consulting. From 1996 to 1999,… | Director | SELL | 858 | $160.4K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 4 | RVMD 10b5-1 | Patel SushilSushil Patel has served as a member of our Board and as our Chief Executive Officer since April 2024. Previously, Dr. Patel served as our Chief Strategy Officer from January 2023 to April 2024 and as our Chief Commercial Officer from May 2021 to January 2023. Prior to joining Replimune, Dr. Patel served as VP, Franchise Head for Lung, Skin, Tumor Agnostic, and Rare Cancers at Genentech, Inc. since April 2018, and previously held various positions of increasing responsibility at Genentech, Inc. since 2002, including global launch lead and lifecycle leader for Tecentriq in lung cancer. From 1999 to 2002, Dr. Patel served as Senior Consultant at Front Line Strategic Management Consulting. From 1996 to 1999,… | Director | SELL | 300 | $56.3K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 4 | RVMD 10b5-1 | Patel SushilSushil Patel has served as a member of our Board and as our Chief Executive Officer since April 2024. Previously, Dr. Patel served as our Chief Strategy Officer from January 2023 to April 2024 and as our Chief Commercial Officer from May 2021 to January 2023. Prior to joining Replimune, Dr. Patel served as VP, Franchise Head for Lung, Skin, Tumor Agnostic, and Rare Cancers at Genentech, Inc. since April 2018, and previously held various positions of increasing responsibility at Genentech, Inc. since 2002, including global launch lead and lifecycle leader for Tecentriq in lung cancer. From 1999 to 2002, Dr. Patel served as Senior Consultant at Front Line Strategic Management Consulting. From 1996 to 1999,… | Director | SELL | 100 | $18.9K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 4 | RVMD 10b5-1 | Patel SushilSushil Patel has served as a member of our Board and as our Chief Executive Officer since April 2024. Previously, Dr. Patel served as our Chief Strategy Officer from January 2023 to April 2024 and as our Chief Commercial Officer from May 2021 to January 2023. Prior to joining Replimune, Dr. Patel served as VP, Franchise Head for Lung, Skin, Tumor Agnostic, and Rare Cancers at Genentech, Inc. since April 2018, and previously held various positions of increasing responsibility at Genentech, Inc. since 2002, including global launch lead and lifecycle leader for Tecentriq in lung cancer. From 1999 to 2002, Dr. Patel served as Senior Consultant at Front Line Strategic Management Consulting. From 1996 to 1999,… | Director | SELL | 600 | $114.3K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 4 | RVMD 10b5-1 | Patel SushilSushil Patel has served as a member of our Board and as our Chief Executive Officer since April 2024. Previously, Dr. Patel served as our Chief Strategy Officer from January 2023 to April 2024 and as our Chief Commercial Officer from May 2021 to January 2023. Prior to joining Replimune, Dr. Patel served as VP, Franchise Head for Lung, Skin, Tumor Agnostic, and Rare Cancers at Genentech, Inc. since April 2018, and previously held various positions of increasing responsibility at Genentech, Inc. since 2002, including global launch lead and lifecycle leader for Tecentriq in lung cancer. From 1999 to 2002, Dr. Patel served as Senior Consultant at Front Line Strategic Management Consulting. From 1996 to 1999,… | Director | SELL | 541 | $103.8K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 4 | RVMD 10b5-1 | Patel SushilSushil Patel has served as a member of our Board and as our Chief Executive Officer since April 2024. Previously, Dr. Patel served as our Chief Strategy Officer from January 2023 to April 2024 and as our Chief Commercial Officer from May 2021 to January 2023. Prior to joining Replimune, Dr. Patel served as VP, Franchise Head for Lung, Skin, Tumor Agnostic, and Rare Cancers at Genentech, Inc. since April 2018, and previously held various positions of increasing responsibility at Genentech, Inc. since 2002, including global launch lead and lifecycle leader for Tecentriq in lung cancer. From 1999 to 2002, Dr. Patel served as Senior Consultant at Front Line Strategic Management Consulting. From 1996 to 1999,… | Director | SELL | 881 | $169.7K | −19.5%hist | +11.6%hist |
| 6/24/2026 | Form 4 | RVMD 10b5-1 | Anders JackJack Anders has served as our Chief Financial Officer since September 2022, as our Senior Vice President, Finance from March 2021 to September 2022 and as our Vice President, Finance from August 2018 to March 2021. Prior to joining Revolution Medicines, Mr. Anders held various positions of increasing responsibility at Depomed, Inc., a specialty pharmaceutical company, from 2006 to July 2018, most recently as its Vice President of Finance. Mr. Anders held various managerial roles in finance and accounting at Elan Pharmaceuticals, Yahoo! and Novellus Systems. Mr. Anders began his career in the life sciences practice at PricewaterhouseCoopers LLP. He received a B.A. in Economics, with an emphasis in… | Chief Financial Officer | SELL | 300 | $51.1K | — | — |
| 6/24/2026 | Form 4 | RVMD 10b5-1 | Anders JackJack Anders has served as our Chief Financial Officer since September 2022, as our Senior Vice President, Finance from March 2021 to September 2022 and as our Vice President, Finance from August 2018 to March 2021. Prior to joining Revolution Medicines, Mr. Anders held various positions of increasing responsibility at Depomed, Inc., a specialty pharmaceutical company, from 2006 to July 2018, most recently as its Vice President of Finance. Mr. Anders held various managerial roles in finance and accounting at Elan Pharmaceuticals, Yahoo! and Novellus Systems. Mr. Anders began his career in the life sciences practice at PricewaterhouseCoopers LLP. He received a B.A. in Economics, with an emphasis in… | Chief Financial Officer | SELL | 9,496 | $1.60M | — | — |
| 6/24/2026 | Form 4 | RVMD 10b5-1 | Anders JackJack Anders has served as our Chief Financial Officer since September 2022, as our Senior Vice President, Finance from March 2021 to September 2022 and as our Vice President, Finance from August 2018 to March 2021. Prior to joining Revolution Medicines, Mr. Anders held various positions of increasing responsibility at Depomed, Inc., a specialty pharmaceutical company, from 2006 to July 2018, most recently as its Vice President of Finance. Mr. Anders held various managerial roles in finance and accounting at Elan Pharmaceuticals, Yahoo! and Novellus Systems. Mr. Anders began his career in the life sciences practice at PricewaterhouseCoopers LLP. He received a B.A. in Economics, with an emphasis in… | Chief Financial Officer | SELL | 4,553 | $761.9K | — | — |
| 6/24/2026 | Form 4 | RVMD 10b5-1 | Anders JackJack Anders has served as our Chief Financial Officer since September 2022, as our Senior Vice President, Finance from March 2021 to September 2022 and as our Vice President, Finance from August 2018 to March 2021. Prior to joining Revolution Medicines, Mr. Anders held various positions of increasing responsibility at Depomed, Inc., a specialty pharmaceutical company, from 2006 to July 2018, most recently as its Vice President of Finance. Mr. Anders held various managerial roles in finance and accounting at Elan Pharmaceuticals, Yahoo! and Novellus Systems. Mr. Anders began his career in the life sciences practice at PricewaterhouseCoopers LLP. He received a B.A. in Economics, with an emphasis in… | Chief Financial Officer | SELL | 5,651 | $956.4K | — | — |
| 6/17/2026 | Form 4 | RVMD 10b5-1 | Horn Margaret AMs. Horn has served on the board of directors of Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a biotechnology company, since December 2022. She received a B.S. in Pharmacy from the University of the Sciences in Philadelphia, a J.D. from the Villanova University Charles Widger School of Law and an executive M.B.A. from the Pennsylvania State University. Alan Sandler, M.D. has served as our Chief Development Officer since September 2025. Previously, Dr. Sandler served as Chief Medical Officer of ALX Oncology Holdings, Inc. from November 2024 until September 2025, where he led clinical strategy and advanced the company’s immune-oncology pipeline. Before ALX Oncology Holdings, he was Chief Medical Officer of… | Chief Operating Officer | SELL | 29,600 | $4.74M | — | — |
| 6/16/2026 | Form 4 | RVMD 10b5-1 | Kelsey Stephen Michael | Officer | SELL | 4,175 | $651.8K | −0.93%hist | +26.2%hist |
Chart shows split-adjusted close for the last three years, or the selected date range. Triangles mark open-market Form 4 purchases and sales in that window.